BeiGene
BGNE
#963
Rank
S$27.14 B
Marketcap
$239.18
Share price
1.02%
Change (1 day)
1.82%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Net assets

Net assets on the balance sheet as of September 2024 : S$4.65 Billion

According to BeiGene 's latest financial reports the company has S$4.65 Billion in net assets.
A companyโ€™s net assets is the sum of its assets minus the sum of its liabilities.

BeiGene - Net assets on balance sheet (from 2014 to 2024)

Net assets by year

Year Net assets Change
2023-12-31$S$4.67 B-20.5%
2022-12-31$S$5.87 B-29.12%
2021-12-31$S$8.29 B61.97%
2020-12-31$S$5.11 B288.08%
2019-12-31$S$1.31 B-44.94%
2018-12-31$S$2.39 B161.78%
2017-12-31$S$0.91 B79.18%
2016-12-31$S$0.51 B385.86%
2015-12-31$S$0.10 B208.76%
2014-12-31$S$34.04 M-169.39%
2013-12-31$-S$49.07 Million

Net assets for similar companies or competitors

Company Net assets differencediff. Country
S$8.15 M-99.82%๐Ÿ‡บ๐Ÿ‡ธ USA
S$1.90 B-59.16%๐Ÿ‡บ๐Ÿ‡ธ USA